Sonographic evaluation of endothelial function in letrozole and tamoxifen users |
| |
| Institution: | 1. Faculdade de Medicina de Ribeirão Preto – Universidade de São Paulo, Brazil;2. Escola de Ultra-sonografia e Reciclagem Médica de Ribeirão Preto – EURP, Brazil;1. Division of Cardiovascular Medicine, University of Maryland School of Medicine, Baltimore, Maryland;2. Division of Cardiology, University of California San Diego, San Diego, California;3. Department of Medicine, UAB, Hospital Universitari Germans Trias i Pujol, Carretera del Canyet, Barcelona, Spain;1. Medical College of Henan University of Science and Technology, Luoyang 471003, China;2. The Second Affiliated Hospital & Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou 325027, China;3. The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China;1. Department of Physics Research, Institute for Research & Medical Consultations (IRMC), Imam Abdulrahman Bin Faisal University, P.O. Box 1982, Dammam 31441, Saudi Arabia;2. Department of Physics, College of Science, Imam Abdulrahman Bin Faisal University, P.O. Box 1982, Dammam 31441, Saudi Arabia;3. Laboratory of Physics of Materials - Structures and Properties, Department of Physics, Faculty of Sciences of Bizerte, University of Carthage, Zarzouna 7021, Tunisia;4. Department of Nano-Medicine Research, Institute for Research & Medical Consultations (IRMC), Imam Abdulrahman Bin Faisal University, P.O. Box 1982, 31441 Dammam, Saudi Arabia;5. Materials Research Laboratory, Department of Physics, FBAS, International Islamic University (IIU), Islamabad 44000, Pakistan;6. Department of Chemistry, Bharath Institute of Higher Education and Research (BIHER), Bharath University, Chennai 600073, Tamil Nadu, India;2. Department of Embryology at Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran 16635-148, Iran |
| |
| Abstract: | ObjectivesStudies have shown that women previously treated for breast cancer present fewer cardiovascular events, indicating a possible protective effect of tamoxifen treatment. The effects of these aromatase inhibitors on cardiovascular protection remain controversial. The aim of this study was to compare some cardiovascular risk markers among breast cancer survivors following treatment with tamoxifen group (TMXg), letrozole group (LTZg) or no endocrine treatment group (NETg).MethodsA total of 103 breast cancer survivors: 35 using TMXg, 34 using letrozole group (LTZg) and 34 using no endocrine treatment group (NETg) were evaluated. Ultrasonographic evaluation of brachial artery flow-mediated dilation (FMD), carotid intima–media thickness (IMT) and stiffness index (β); blood total cholesterol, HDL and triglycerides were assessed.ResultsAll three groups presented similar values of HDL and IMT. TMXg showed the lowest total cholesterol (219.29 ± 36.31 mg/dL vs. 250.59 ± 38.37 mg/dL vs. 245.09 ± 35.35 mg/dL; TMXg vs. LTZg vs. NETg, respectively; p < 0.01—ANOVA), the highest triglycerides (139.34 ± 41.82 mg/dL vs. 111.35 ± 28.22 mg/dL vs. 122.09 ± 33.42 mg/dL; p < 0.01), the highest FMD (6.32 ± 2.33% vs. 4.10 ± 2.06% vs. 4.66 ± 2.52%; p < 0.01) and the lowest stiffness index (β) (5.08 ± 1.68 vs. 6.28 ± 1.75 vs. 5.99 ± 1.86; p = 0.01). LTZg did not differ significantly from NETg on any evaluated parameter.ConclusionsWe did not observe any effect of LTZg on the evaluated cardiovascular risk parameters compared to NETg. As such, the observed difference on lipid values, stiffness index (β) and FMD between women receiving tamoxifen and letrozole might be best attributed to the beneficial effect of tamoxifen than to a detrimental effect of letrozole. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
